27th Feb 2006 10:40
Vernalis PLC27 February 2006 27 February 2006 Vernalis: Notice of Full Year 2005 Preliminary Results Vernalis plc (LSE: VER, Nasdaq: VNLS) today announces that it will be releasingits preliminary results for the twelve months ended 31 December 2005 onThursday, 16 March 2006. An analyst briefing will be held at 9.30 a.m. on 16 March at the offices ofBrunswick Group, 16 Lincoln's Inn Fields, London WC2A 3ED. -- ends -- Enquiries: Vernalis plc +44 (0) 118 977 3133 Simon Sturge, Chief Executive Officer Tony Weir, Chief Financial Officer Julia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959 Jon Coles Wendel Verbeek Notes to Editors About Vernalis Vernalis is a specialty pharmaceutical company focused on products marketed tospecialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has six products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, propelling the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, specialty pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. Safe Harbour statement: this news release may contain forward-looking statementsthat reflect the Company's current expectations regarding future events.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the successfulintegration of completed mergers and acquisitions and achievement of expectedsynergies from such transactions, and the ability of the Company to identify andconsummate suitable strategic and business combination transactions. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC